Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150924 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2TK1 | |
| SCHEMBL5502298 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2TK1 | |
| SCHEMBL3036948 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2TK1 | |
| Hydrochloric Acid SCHEMBL7928006 | 0.98 | SMN1; SMN2 (0.35) | SMN1; SMN2TK1 | |
| SCHEMBL8286842 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL8288852 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL3470163 | 0.84 | CYP1A2 (0.33) | SMN1; SMN2 | |
| SCHEMBL13201969 | 0.84 | CYP1A2 (0.33) | SMN1; SMN2 | |
| SCHEMBL8288905 | 0.84 | CYP1A2 (0.33) | SMN1; SMN2 | |
| SCHEMBL3470048 | 0.80 | CTSV (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138395-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-7041696-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-05-09 | — | — | US | claimed |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-01-22 | — | — | US | claimed |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180327449-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | disclosed |
| US-9994613-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2017-01-26 | — | — | US | disclosed |
| US-9487555-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-08 | — | — | US | disclosed |
| US-9156880-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | disclosed |
| EP-2270005-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-1286989-A2 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1278737-A2 | PROCESS AND INTERMEDIATES FOR MAKING SUBSTITUTED ASPARTIC ACID ACETALS | Vertex Pharmaceuticals Incorporated (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020013278-A1 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2002-01-31 | — | — | US | disclosed |
| WO-2001090063-A2 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001081330-A2 | PROCESS AND INTERMEDIATES FOR MAKING SUBSTITUTED ASPARTIC ACID ACETALS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1064298-A2 | INHIBITORS OF CASPASES | Vertex Pharmaceuticals Incorporated (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047545-A2 | INHIBITORS OF CASPASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | SMN1; SMN2 678/4885TK1 582/4885 |
| US-20180327449-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | SMN1; SMN2 678/4885TK1 582/4885 |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | SMN1; SMN2 678/4885TK1 582/4885 |
| US-20020013278-A1 | Prodrug of an ice inhibitor | CASP1, MCL1, IL1A | SMN1; SMN2 770/4885TK1 505/4885 |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1R1, IL1B, IL1RN | SMN1; SMN2 4073/4885TK1 1373/4885 |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | SMN1; SMN2 678/4885TK1 582/4885 |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1B, IL1RN, IL1R1 | SMN1; SMN2 4567/4885TK1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.